These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30518005)

  • 21. Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 predicting the future impact of the universal childhood conjugate vaccine program.
    Watson M; Roche P; Bayley K; Bell JM; Collignon P; Gilbert GL; Hogg G; Keil AD; Krause V; Murphy D; Smith HV; Brown M; Stylianopoulos J; Turnidge J
    Commun Dis Intell Q Rep; 2004; 28(4):455-64. PubMed ID: 15745392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines.
    Isaacman DJ; McIntosh ED; Reinert RR
    Int J Infect Dis; 2010 Mar; 14(3):e197-209. PubMed ID: 19700359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characteristics and serotype distribution of invasive pneumococcal disease in pediatric patients from Beijing, China.
    Xu Y; Wang Q; Yao K; Dong F; Song W; Liu G; Xu B; Shi W; Li Y; Li K; Liu Y; Qian S
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1833-1842. PubMed ID: 33786728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.
    Demczuk WH; Martin I; Griffith A; Lefebvre B; McGeer A; Lovgren M; Tyrrell GJ; Desai S; Sherrard L; Adam H; Gilmour M; Zhanel GG; ;
    Can J Microbiol; 2013 Dec; 59(12):778-88. PubMed ID: 24313450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.
    Harboe ZB; Dalby T; Weinberger DM; Benfield T; Mølbak K; Slotved HC; Suppli CH; Konradsen HB; Valentiner-Branth P
    Clin Infect Dis; 2014 Oct; 59(8):1066-73. PubMed ID: 25034421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine.
    Black S; France EK; Isaacman D; Bracken L; Lewis E; Hansen J; Fireman B; Austrian R; Graepel J; Gray S; Klein NP
    Pediatr Infect Dis J; 2007 Sep; 26(9):771-7. PubMed ID: 17721369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early Streptococcus pneumoniae serotype changes in Utah adults after the introduction of PCV13 in children.
    Kendall BA; Dascomb KK; Mehta RR; Stockmann C; Mason EO; Ampofo K; Pavia AT; Byington CL
    Vaccine; 2016 Jan; 34(4):474-478. PubMed ID: 26706276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serotypes, antimicrobial susceptibility, and molecular epidemiology of invasive and non-invasive Streptococcus pneumoniae isolates in paediatric patients after the introduction of 13-valent conjugate vaccine in a nationwide surveillance study conducted in Japan in 2012-2014.
    Nakano S; Fujisawa T; Ito Y; Chang B; Suga S; Noguchi T; Yamamoto M; Matsumura Y; Nagao M; Takakura S; Ohnishi M; Ihara T; Ichiyama S
    Vaccine; 2016 Jan; 34(1):67-76. PubMed ID: 26602268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serotype distribution of Streptococcus pneumoniae isolated from patients with invasive pneumococcal disease in Brazil before and after ten-pneumococcal conjugate vaccine implementation.
    dos Santos SR; Passadore LF; Takagi EH; Fujii CM; Yoshioka CR; Gilio AE; Martinez MB
    Vaccine; 2013 Dec; 31(51):6150-4. PubMed ID: 23747454
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twenty year surveillance of invasive pneumococcal disease in Nottingham: serogroups responsible and implications for immunisation.
    Ispahani P; Slack RC; Donald FE; Weston VC; Rutter N
    Arch Dis Child; 2004 Aug; 89(8):757-62. PubMed ID: 15269078
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska.
    Bruce MG; Singleton R; Bulkow L; Rudolph K; Zulz T; Gounder P; Hurlburt D; Bruden D; Hennessy T
    Vaccine; 2015 Sep; 33(38):4813-9. PubMed ID: 26247901
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recommendations for the prevention of Streptococcus pneumoniae infections in infants and children: use of 13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPSV23).
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2010 Jul; 126(1):186-90. PubMed ID: 20498180
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolving picture of invasive pneumococcal disease in massachusetts children: a comparison of disease in 2007-2009 with earlier periods.
    Yildirim I; Stevenson A; Hsu KK; Pelton SI
    Pediatr Infect Dis J; 2012 Oct; 31(10):1016-21. PubMed ID: 22673142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early Changes in the Serotype Distribution of Invasive Pneumococcal Isolates from Children after the Introduction of Extended-valent Pneumococcal Conjugate Vaccines in Korea, 2011-2013.
    Cho EY; Choi EH; Kang JH; Kim KH; Kim DS; Kim YJ; Ahn YM; Eun BW; Oh SH; Cha SH; Cho HK; Hong YJ; Kim KN; Kim NH; Kim YK; Kim JH; Lee H; Lee T; Kim HM; Lee KS; Kim CS; Park SE; Kim YM; Oh CE; Ma SH; Jo DS; Choi YY; Lee J; Bae GR; Park O; Park YJ; Kim ES; Lee HJ
    J Korean Med Sci; 2016 Jul; 31(7):1082-8. PubMed ID: 27366006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Invasive pneumococcal disease in children prior to implementation of the conjugate vaccine in the Zurich region, Switzerland.
    Gessler P; Martin F; Suter D; Berger C
    Acta Paediatr; 2010 Jul; 99(7):1005-10. PubMed ID: 20219035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epidemiology and evolution of invasive pneumococcal disease caused by multidrug resistant serotypes of 19A in the 8 years after implementation of pneumococcal conjugate vaccine immunization in Dallas, Texas.
    Techasaensiri C; Messina AF; Katz K; Ahmad N; Huang R; McCracken GH
    Pediatr Infect Dis J; 2010 Apr; 29(4):294-300. PubMed ID: 19949357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 32-Year Study of the Effect of Pneumococcal Vaccines on Invasive Streptococcus pneumoniae Disease.
    Stanek RJ; Norton NB; Mufson MA
    Am J Med Sci; 2016 Dec; 352(6):563-573. PubMed ID: 27916211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distribution of capsular types and drug resistance patterns of invasive pediatric Streptococcus pneumoniae isolates in Teheran, Iran.
    Houri H; Tabatabaei SR; Saee Y; Fallah F; Rahbar M; Karimi A
    Int J Infect Dis; 2017 Apr; 57():21-26. PubMed ID: 28131730
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal meningitis in children.
    Ruiz-Contreras J; Picazo J; Casado-Flores J; Baquero-Artigao F; Hernández-Sampelayo T; Otheo E; Méndez C; Del Amo M; Balseiro C;
    Vaccine; 2017 Aug; 35(35 Pt B):4646-4651. PubMed ID: 28711388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.